DAWN
Day One Biopharmaceuticals, Inc.
Day One Biopharmaceuticals, Inc. (DAWN) has 6 SEC Form 4 filings (32 transaction rows) in the rolling window, disclosed by 4 distinct insiders. Most recent filing: Apr 23, 2026.
Insiders have net sold $392K over the trailing 6 months.
- Industry:Biotechnology
- CEO:Jeremy Bender
- Employees:181
- HQ:Brisbane, CA, US
- IPO:2021-05-27
Insider Buying
$0
reported purchases (SEC code P)
Insider Selling
$392K
reported sales (SEC code S)
Unique Insiders
4
in the rolling window
| Source | ||||||
|---|---|---|---|---|---|---|
Merendino LaurenFirst filing | Chief Commercial Officer | Sale | 5,814 | $67K | Feb 18 | SEC ↗ |
Bender JeremyFirst filing | CHIEF EXECUTIVE OFFICER | Sale | 15,459 | $179K | Feb 18 | SEC ↗ |
York Charles N IIFirst in 3 months | COO and CFO | Sale | 6,065 | $70K | Feb 18 | SEC ↗ |
Dubow AdamFirst filing | Gen Counsel & Secretary | Sale | 4,319 | $39K | Nov 18 | SEC ↗ |
York Charles N IIFirst filing | COO and CFO | Sale | 4,062 | $36K | Nov 18 | SEC ↗ |
Related companies
Day One Biopharmaceuticals, Inc. is in the Healthcare sector.